This phase II trial is testing a new targeted therapy in patients with B-cell Non-Hodgkin Lymphoma, whose cancer has got worse or will not respond to other treatments.
This trial is treating patients with B-cell Non-Hodgkin Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Commercial Sponsor
Regeneron Pharmaceuticals
Summary
Eligible patients will be randomised according to their B-cell Non-Hodgkin Lymphoma diagnosis, each receiving intravenous infusion with REGN1979.
Recruiting Hospitals Read More